跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-19AI 评分23

EyePoint III 期试验失败及礼来中国药物递送协议

EyePoint's Phase 3 failure; Lilly's China drug delivery deal

AI 导读

总部位于马萨诸塞州 WaterTown 的生物科技公司 EyePoint 宣布其 III 期试验失败。受此影响,该公司将对员工进行大规模裁员。同一天,礼来(Lilly)也与中国某公司达成了药物递送领域的合作协议。

正文

Plus news about Long­wood’s next fund and Ryzumvi’s la­bel ex­pan­sion.

Eye­Point drug fails, biotech halves staff: The Wa­ter­town, MA-based biotech is let­ting go of

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news